FDA Official Steps Down, Sued by Drugmaker

FDA Activity Recap: October 2025 Features New Platform Technology Designation, RDEA Pilot Program Selection, and More – automotivemogul

Last month, October 2025, the CGTLive® team was diligently tracking the FDA’s activities related to the development of cell and gene therapies for the treatment of rare, complex, and otherwise challenging diseases and disorders. The agency has continued to …

FDA Drug Unit chief resigns as he is sued

George Tidmarsh, the head of the FDA’s drug division, resigned on Sunday after he was placed on leave Friday, “after the Office of the General Counsel and the Office of the Inspector General were notified of serious concerns about his personal conduct,” Emily Hilliard, an HHS spokeswoman, told ABC News in a statement. Tidmarsh said… The post FDA Drug Unit chief resigns as he is sued appeared first on Drug Discovery and Development.

FDA Official Steps Down, Sued by Drugmaker

(WSJ) – George Tidmarsh, who resigned Sunday, is accused in a lawsuit of seeking a bribe and defaming a drug A Food and Drug Administration official who resigned on Sunday was sued by a Canadian pharmaceutical company, which accused him of soliciting a bribe and tanking its stock with false statements as part of a revenge campaign against a former colleague. (Read More)

Tidmarsh’s FDA exit marks latest high-profile jockeying at US agencies - Pharmaceutical Technology

The resignation of the FDA's head drug regulator George Tidmarsh comes amid concerns about conduct related to lupus nephritis drug Lupkynis.